Claraphi Advisory Network’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Claraphi Advisory Network’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-24,918	Closed	-$84K	–	318
2020 Q2	$84K	Buy	24,918 +20,914	+522%	+$98.9K	0.04%	268
2020 Q1	$15K	Sell	4,004 -7,650	-66%	-$35.5K	0.01%	702
2019 Q4	$70K	Sell	11,654 -3,090	-21%	-$21.1K	0.04%	199
2019 Q3	$111K	Sell	14,744 -2,759	-16%	-$31.1K	0.07%	240
2019 Q2	$237K	Buy	17,503 +5,532	+46%	+$63.9K	0.14%	190
2019 Q1	$65K	Buy	+11,971	New	+$58.2K	0.04%	232

Other funds holding ZYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

PCM

Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Claraphi Advisory Network's ZYNE Position: Q3 2020 in Review

Claraphi Advisory Network sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2020, closing a stake of 24,918 shares — an estimated $84K sold.

Claraphi Advisory Network first reported a position in ZYNE in Q1 2019 and held it in 6 quarters. The position peaked at $237K in Q2 2019. 66 funds tracked by Wall St. Rank hold ZYNE as of Q3 2020.

Claraphi Advisory Network reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2020 after selling out during the quarter.
Claraphi Advisory Network sold 24,918 Zynerba Pharmaceuticals, Inc shares in Q3 2020, an estimated $84K.
Claraphi Advisory Network first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2019 and held it in 6 quarters.
Claraphi Advisory Network's Zynerba Pharmaceuticals, Inc position peaked at $237K in Q2 2019.
66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2020.

Based on Claraphi Advisory Network's 13F filing for Q3 2020, filed 13 Nov 2020.